KP104 ( DrugBank: - )

3 diseases

ID	Disease name (Link within this page)	Number of trials
49	Systemic lupus erythematosus	1
62	Paroxysmal nocturnal hemoglobinuria	2
66	IgA nephropathy	1

49. Systemic lupus erythematosus

Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05504187 (ClinicalTrials.gov)	October 2023	15/8/2022	Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus	An Open-label, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104 in Subjects With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: KP104	Kira Pharmacenticals (US), LLC.	NULL	Not yet recruiting	18 Years	65 Years	All	24	Phase 2	NULL

Clinical trials : 292 / Drugs : 151 - (DrugBank : 49) / Drug target genes : 22 - Drug target pathways : 108

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05476887 (ClinicalTrials.gov)	November 25, 2022	25/7/2022	To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104	An Open-label, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104 in Complement Inhibitor-naïve Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)	Paroxysmal Nocturnal Hemoglobinuria	Drug: KP104	Kira Pharmacenticals (US), LLC.	NULL	Recruiting	18 Years	N/A	All	35	Phase 2	China
2	NCT05490017 (ClinicalTrials.gov)	December 30, 2020	4/8/2022	To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104	SYNERGY-1: A Phase 1 First-in-human, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104 in Healthy Subjects	Paroxysmal Nocturnal Hemoglobinuria	Drug: KP104;Drug: Placebo	Kira Pharmacenticals (US), LLC.	NULL	Completed	18 Years	55 Years	All	80	Phase 1	Australia

Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05517980 (ClinicalTrials.gov)	July 1, 2023	24/8/2022	Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis	An Open-label, Phase 2 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 in Subjects With IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G)	Glomerulonephritis	Drug: KP104	Kira Pharmacenticals (US), LLC.	NULL	Not yet recruiting	18 Years	75 Years	All	52	Phase 2	NULL